Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)

PSA screening reduces PCa-mortality but the disadvantages overdiagnosis and overtreatment require multivariable risk-prediction tools to select appropriate treatment or active surveillance. This review explains the differences between the two largest screening trials and discusses the drawbacks of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephan, Carsten, Rittenhouse, Harry, Hu, Xinhai, Cammann, Henning, Jung, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Communications and Publications Division (CPD) of the IFCC 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975191/
https://www.ncbi.nlm.nih.gov/pubmed/27683457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975191/
https://www.ncbi.nlm.nih.gov/pubmed/27683457

Ejemplares similares